WuXi Biologics (02269.HK) sees profit growth, with expected profit attributable to equity shareholders increasing by approximately 56% year-on-year in the first half of the year.

China Fortune Finance and Economics APP News, WuXi Biologics (02269.HK) announced that the group expects its revenue in the first half of 2025 to increase by about 16% compared to the same period last year; the gross profit margin is expected to increase by about 3.6% year-on-year; profit and profit attributable to equity shareholders of the company are expected to increase by about 54% and about 56% respectively compared to the same period last year; and after adjusting for share-based compensation, foreign exchange gains and losses, and equity investment gains and losses, the company's adjusted net profit under non-International Financial Reporting Standards is expected to increase by about 11%.